NCT07325539招募中2 期
Low-dose Radiotherapy (LDRT) Combined With Toripalimab and GP Chemotherapy for Recurrent/Metastatic Nasopharyngeal Carcinoma (LIGHT): A Multicentre, Open-Label, Single-Arm Phase II Clinical Study
Sun Yat-sen University2 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2026年1月12日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
- 试验地点
- 2
- 主要终点
- Progression-free survival (PFS) assessed by RECIST 1.1
研究概览
简要总结
This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-65 years old.
- •Histologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II or III).
- •ECOG Performance Status score of 0-
- •At least one measurable lesion as per RECIST v1.1 criteria.
- •Patients with newly diagnosed metastatic NPC, or patients with locoregionally advanced NPC who developed metastasis ≥6 months or recurrence ≥12 months after completing radical radiotherapy/chemotherapy for the primary lesion.
- •No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent/metastatic lesions.
- •Adequate organ function, meeting the following criteria within 7 days prior to treatment:
- •Hematological criteria (without transfusion or hematopoietic growth factor support within 14 days):
- •Hemoglobin (Hb) ≥90 g/L.
- •White Blood Cell (WBC) count ≥4.0 × 10⁹/L.
- •Platelet count (PLT) ≥100 × 10⁹/L.
- •Biochemical criteria:
- •Total Bilirubin (TBIL) ≤1.5 × Upper Limit of Normal (ULN).
- •Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤2.5 × ULN.
- •Serum Creatinine (Cr) ≤1.5 × ULN AND Creatinine Clearance (CCr) ≥60 mL/min.
- •Coagulation function: INR and APTT ≤1.5 × ULN.
- •Normal results for myocardial injury markers, heart failure markers, and electrocardiogram (ECG). For patients with abnormal results in any of these, the investigator will assess the need for Doppler echocardiography.
- •Thyroid function: TSH ≤ ULN. If abnormal, FT3 and FT4 levels should be considered; patients can be enrolled if FT3 and FT4 levels are normal.
- •Women of childbearing potential must have used reliable contraception, have a negative serum pregnancy test within 7 days before enrollment, and be willing to use adequate contraception during the trial and for 8 weeks after the last dose of the study drug, or be surgically sterile. Men must agree to use adequate contraception or be surgically sterile during the trial and for 8 weeks after the last dose.
- •Voluntary provision of signed informed consent, with good compliance.
排除标准
- •Disease progression within 6 months after completing standard treatment for locoregionally advanced nasopharyngeal carcinoma.
- •Absence of identifiable tumor lesions in both the primary site and locoregional lymph nodes, precluding the development of an LDRT plan.
- •Inability to undergo MRI due to reasons such as implanted metal devices or claustrophobia.
- •Requirement for systemic use of corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose or during the study. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg/day prednisone equivalent are permitted in the absence of active autoimmune disease. Physiological replacement doses of corticosteroids (≤10 mg/day prednisone equivalent) are allowed.
- •Recurrent target lesions suitable for curative surgery or a second course of radiotherapy.
- •History of any active autoimmune or autoimmune disease, or known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. Exceptions include type I diabetes, hypothyroidism requiring hormone replacement therapy, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia).
- •Active or uncontrolled severe infection (≥CTCAE Grade 3) within 4 weeks prior to enrollment.
- •History of active tuberculosis within the past year, regardless of treatment. Patients with a history of active pulmonary tuberculosis over 1 year ago who have documented evidence of adequate past anti-tuberculosis treatment may be considered; otherwise, they are excluded.
- •History of hypertension that cannot be adequately controlled with a single antihypertensive medication (systolic BP ≥150 mmHg or diastolic BP ≥90 mmHg).
- •Clinically significant bleeding symptoms or definite bleeding tendency, specifically excluding cases of local recurrence with high bleeding risk or cases within 1 year post-radiotherapy assessed to have a high risk of necrosis.
- •Urinalysis showing urine protein ≥ ++ AND confirmed 24-hour urine protein ≥1.0 g.
- •Myocardial ischemia (above Grade I), myocardial infarction, arrhythmia (including QTc ≥480 ms), or ≥ Grade 2 congestive heart failure (NYHA classification) within 6 months prior to enrollment.
- •If an echocardiogram is required per Inclusion Criterion 7(4), results showing Left Ventricular Ejection Fraction (LVEF) below the lower limit of normal (60%).
- •Diagnosis of other malignancies within 5 years prior to enrollment, except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma.
- •Presence of leptomeningeal or central nervous system metastases.
- •HIV positive, TP positive, liver cirrhosis, decompensated liver disease, active hepatitis (uncontrolled active hepatitis despite treatment: Hepatitis B - HBsAg positive and HBV DNA ≥1 × 10⁴ copies/mL; Hepatitis C - HCV RNA positive with abnormal liver function; co-infection with HBV and HCV) requiring antiviral therapy.
- •Participation in another anti-tumor drug clinical trial within 4 weeks prior to enrollment.
- •Administration of any live attenuated vaccine within 30 days prior to enrollment.
- •Contraindications to radiotherapy.
- •Known allergy to the study drug or any of its excipients, or history of severe allergic reactions to other monoclonal antibodies.
- •History of psychoactive drug abuse unable to be abstained, or presence of psychiatric disorders.
- •Any other condition assessed by the investigator as potentially endangering the patient's safety or compliance, including severe concurrent diseases (including psychiatric disorders) requiring prompt treatment, severely abnormal laboratory test results, or other psychological, familial, or sociological factors deemed high-risk.
研究组 & 干预措施
LDRT + Toripalimab + GP chemotherapy
Experimental
Patients will receive LDRT plus toripalimab and GP chemotherapy for 4-6 cycles, then followed by toripalimab until disease progression or unacceptable toxicity.
干预措施: LDRT (Radiation)
LDRT + Toripalimab + GP chemotherapy
Experimental
Patients will receive LDRT plus toripalimab and GP chemotherapy for 4-6 cycles, then followed by toripalimab until disease progression or unacceptable toxicity.
干预措施: Gemcitabine(GEM) (Drug)
LDRT + Toripalimab + GP chemotherapy
Experimental
Patients will receive LDRT plus toripalimab and GP chemotherapy for 4-6 cycles, then followed by toripalimab until disease progression or unacceptable toxicity.
干预措施: Toripalimab (Drug)
LDRT + Toripalimab + GP chemotherapy
Experimental
Patients will receive LDRT plus toripalimab and GP chemotherapy for 4-6 cycles, then followed by toripalimab until disease progression or unacceptable toxicity.
干预措施: Cisplatin (Drug)
结局指标
主要结局
Progression-free survival (PFS) assessed by RECIST 1.1
时间窗: up to approximately 2 years
PFS was defined as the time from enrollment to the first occurrence of disease progression as determined according to RECIST v1.1 or death from any cause, whichever occurs first.
次要结局
- Progression-free survival (PFS) assessed by iRECIST(up to approximately 2 years)
- Objective Response Rate（ORR）(up to approximately 2 years)
- Overall survival (OS)(up to approximately 4 years)
- Adverse events(up to approximately 2 years)
研究者
Jun Ma, MD
Professor
Sun Yat-sen University
研究点 (2)
Loading locations...
相似试验
招募中
2 期
RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal Cancer Study Group2024-513914-36-00Goethe University Frankfurt180
招募中
3 期
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with extensive stage small-cell lung cancer?2023-505514-15-00Norwegian University Of Science And Technolology310
招募中
2 期
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerOropharyngeal CancerNCT07290621University of Chicago30
尚未招募
2 期
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver MetastasesNCT07258147Sichuan University30
招募中
3 期
Lomustine with or without a second round of brain radiation for the reappearance of glioblastomaGlioblastoma2023-505267-36-00European Organisation For Research And Treatment Of Cancer, European Organisation For Research And Treatment Of Cancer399